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B OTR YOCC0C US BRA UNII TRITERPENE
SYNTHASE PROTEINS AND NUCLEIC ACID
MOLECULES, AND METHODS FOR THEIR
USE

synthase in particular a botryococcene synthase, BBS,
enZyme. The identi?cation of the botryococcene synthase
gene noW provides an alternative means of generating impor
tant raW materials for the reliable and cost effective produc
tion of an energy-rich, reneWable, and sustainable biofuel

CLAIM TO PRIORITY

source (FIG. 3). For example, the co-expression of the bot
ryococcene synthase gene in combination With a suitable FPP

This application is a divisional of US. application Ser. No.
12/539,442, ?led Aug. 11, 2009, now US. Pat. No. 7,985,
568, Which claims priority under 35 U.S.C. 119(e) to US.

synthase and triterpene methyltransferase genes in transgenic
terrestrial or aquatic plants could yield a production platform
for the methylated triterpenes. These compounds could be

provisional application No. 61/087,920 ?led Aug. 11, 2008,
incorporated in its entirety by reference.

derived from the metabolic diversion of CO2 ?xed in the

process of photosynthesis ?oWing directly into triterpene bio
synthesis and accumulation. The feasibility of this engineer
ing strategy for the production of large amounts of high
valued sesquiterpenes, terpenes consisting of 15 carbons

SEQUENCE LISTING
The instant application contains a Sequence Listing Which
has been submitted via EFS-Web and is hereby incorporated

rather than the 30 carbons found in triterpenes, Was recently

by reference in its entirety. Said ASCII copy, created on Oct.

demonstrated. (Wu et al., (2006) Nature Biotechnology
1441 1447).

12, 2009, is named 14726673.txt, and is 14,577 bytes in siZe.
FIELD OF THE INVENTION

20

This invention relates to a triterpene synthase, in particular
a botryococcene synthase, proteins and nucleic acid mol

famesyl diphosphate (FPP) substrate molecules yielding bot

ecules and their use.

BACKGROUND OF THE INVENTION

Squalene and botryococcene are related by their putative
biosynthetic origins from the condensation of tWo famesyl
diphosphate (FPP) molecules, and are knoWn to be synthe
siZed byrace B, a fresh Water green algae (Okada. et al.,

25

ryococcene, a 30-carbon, branched-chain hydrocarbon.
More speci?cally, disclosed herein is the DNA and protein
sequence of, and the functional characterization for, the race
B botryococcene synthase gene Which, When expressed in a
heterologous host such as bacteria, yeast or plants yields a

protein that, When mixed With a lysate and reducing equiva
30

lents in the form of NADPH, provides an enZyme activity that
catalyZes a unique chemical condensation of 2 FPP mol

ecules, creating a branched, triterpene hydrocarbon knoWn as
botryococcene. A schematic diagram of the reaction cata
lyZed by the botryococcene synthase enZyme is shoWn in
FIG. 1. Like squalene synthase (Blagg et al., (2002) J. Am.

(1995). Journal OfApplied Phycology 555-559; MetZger and

Largeau (2005). Applied Microbiology and Biotechnology
486-496.) Botryococcene is further modi?ed in and becomes
methylated With 1, 2, 3 or 4 additional methyl substituents

catalyZed by a special triterpene methyl transferase. Botryo

The botryococcene synthase of this invention is a triterpene
synthase enZyme catalyZing the reductive condensation of 2

35

cocene and its methylated derivatives have attracted signi?

Chem. Soc. 8846-8853), botryococcene synthase is predicted

cant attention because these molecules are thought to be the

to catalyZe a 2 step reaction. The ?rst step condenses the 2
FPP substrate molecules into a pre-squalene diphosphate

progenitors to current oil shale deposits (Summons et al.,

intermediate (PSPP). When NADPH is provided, squalene

(2002) Organic Geochemistry 99-109; Walters et al., (2005)
Aapg Bulletin 1239-1 244.) and because they are considered

synthase reduces the PSPP to a linkage of carbons 1 and 1' of
40

promising reneWable, alternative biofuels (Banerjee et al.,
(2002). Critical Reviews in Biotechnology 245-279.) For
example, Hillen et al. (1982) Biotechnology And Bioengi
neering 193-205) previously reported on the catalytic crack

ing of methylated botryococcenes and squalene derivatives,

linkage of carbon 3 of one FPP starter molecule to carbon 1'
of the second FPP starter molecule.
45

BRIEF DESCRIPTION OF THE DRAWINGS

and observed an overall conversion of 97% of the oil to

combustible fuels under standard cracking conditions. Over
all, 67% of the oil Was converted to gasoline grade fuel, 15%

FIG. 1 depicts the biosynthetic pathWays for botryococ
cene and squalene. Both triterpenes are derived from an initial

to aviation turbine fuel, and 15% to diesel fuel With a residual

of only 3%. Hence, catalytic hydrolysis (as performed in
standard petroleum re?neries) of these highly branched,
poly-unsaturated triterpenes results in the generation of

50

reduced to form either botryococcene or squalene.
FIG. 2 depicts an overvieW of the hydrocracking process of
a typical, C34 botryococcene to yield fuel suitable for com
55

feedstocks for chemical manufacturing (Banerjee et al.,

(2002)).
60

type culturing conditions (Casadevall et al., (1985). Biotech

biofuels production platform into terrestrial or aquatic plants.
Genes coding for the biochemical steps for synthesis of bot
ryococcocenes Would be introduced into plants such that the

nology and Bioengineering 286-295).

respective catalytic steps (FPP synthase, triterpene synthase
and triterpene methyltransferase activities) Would be targeted

BRIEF DESCRIPTION OF THE INVENTION
65

The current disclosure describes the functional identi?ca
tion and characterization of the gene coding for a triterpene

bustion engines. Brie?y, botryococcocenes are treated With
high pressure H2 at high temperatures With a Pd catalyst to
give a variety of organic molecules, Which can be further
distilled into various classes of fuel.
FIG. 3 depicts a strategy for engineering an alternative

Up to this time, these energy-rich triterpene oils have only
been available from cultures of a rather sloW groWing green
algae that does not lend itself to large-scale or fermentation

condensation of 2 FPP molecules to form presqualene

diphosphate (PSPP), Which is subsequently cleaved and

hydrocarbon fractions that are chemically equivalent to those
derived from current petroleum deposits and are of direct
utility as fuels for internal combustion engines, as Well as

the respective FPP molecules. In contrast, When botryococ
cene synthase is provided NADPH, the PSPP undergoes a
different reducing rearrangement to botryococcene With a

to the chloroplast compartment. The introduced enZyme
activities Would hence divert photosynthetically ?xed CO2

directly into methylated triterpene biosynthesis.

US 8,592,180 B2
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FIG. 4 presents the DNA sequence for the botryococcene
synthase cDNA, SEQ ID NO: 1. The start and stop codons are
shown in bold.
FIG. 5 presents the amino acid sequence for the botryococ

cene synthase, BBS, enzyme, nucleic acid molecules e.g,

SEQ ID NO: 1, encoding a botryococcene synthase, BBS,
polypeptide of this invention, e.g., SEQ ID NO: 2 and meth
ods for their use.

The polypeptides of this invention include for example
polypeptides comprising the amino acid sequence set forth in

cene synthase protein, SEQ ID NO: 2, predicted from the
corresponding cDNA sequence shoWn in FIG. 4.
FIG. 6 depicts an alignment comparison of selection

SEQ ID NO:2 and fragments thereof. Preferably the polypep

regions/domains of various squalene synthase proteins from

tide fragments have triterpene synthase activity. The polypep

Bolryococcus (BSS), tobacco (N. Zabacum), Arabidopsis (A.

tides of this invention may comprise one or more peptide

Zhaliana), corn (Z. mays), rat (R. rallus) and yeast (S. cerevi
siae) to that for the botryococcene synthase (BBS). Domains

domains I, II, III, IV, V and IV, Wherein domain I comprises
LPQELQDPICIFYL (SEQ ID NO: 3), domain II comprises
LRALDTVEDDMN LKSETK (SEQ ID NO: 4), domain III
comprises YCHYVAGSCGIAVTKVIV (SEQ ID NO: 5),
domain IV comprises GLLLQKANIITDYNED (SEQ ID
NO: 6), and domain V comprises ALALLLVTAFGHLS
(SEQ ID NO: 7).

I-VI Were identi?ed as highly conserved amongst diverse

squalene synthases, and domains III-V Were previously cor
related With the particular steps in catalysis as noted.
Sequences displayed across the 5 domains are: BBS, SEQ ID

NO: 3, 4, 5, 6, and 7; BSS, SEQ ID NO: 8, 9, 10, 11, and 12;
N. Zabacum SEQ ID NO: 13, 14, 15, 16, and 17; A. Zhaliana,
SEQ ID NO: 18, 19, 20, 21, and 22; Z. mays, SEQ ID NO: 23,
24, 25, 26 and 27; R. razzus, SEQ ID NO: 28, 29, 30, 31, ans
32; and S. cerevisiae SEQ ID NO: 33, 34, 35, 36 and 37.
FIG. 7 depicts the puri?cation of hexa-histidine tagged
(SEQ ID NO: 44) BBS enzyme. E. coli cells over-expressing
the botryococcene synthase gene harboring an amino termi
nal hexa-histidine puri?cation tag (SEQ ID NO: 44) Were

20

used to prepare an initial cell lysate (crude lysate), Which Was

25

then subject to nickle af?nity chromatography. The crude
lysate Was applied to the a?inity column, folloWed by Wash
ing With buffer containing increasing concentrations of imi
dazole (?oW (buffer Without imidazole, to buffer containing
250 mM imidazole) and the respective column fractions col

30

The polypeptides of this invention may also contain one or
more modi?ed amino acids. The presence of modi?ed amino

stability. Amino acid(s) are modi?ed, for example, co-trans

lationally or post-translationally during recombinant produc
tion (e. g., N-linked glycosylation at NiXiS/T motifs dur

ing expression in mammalian cells) or modi?ed by synthetic

lected for SDS-PAGE analysis.Aliquots of each fraction Were

resolved by SDS-PAGE and the gel stained With Coomassie
Blue, a general protein stain. Molecular Weight standards are
noted as marker and the expected size for the his-tagged BBS
protein is noted by the arroW.
FIG. 8 illustrates the botryococcene synthase enzyme

acids may be advantageous in, for example, increasing triter
pene synthase catalytic activity or increasing polypeptide

35

means.Accordingly, a “mutant”, “variant” or “modi?ed” pro
tein, enzyme, polynucleotide, gene, or cell, means a protein,
enzyme, polynucleotide, gene, or cell, that has been altered or
derived, or is in some Way different or changed, from a parent
protein, enzyme, polynucleotide, gene, or cell. A mutant or
modi?ed protein or enzyme is usually, although not necessar
ily, expressed from a mutant polynucleotide or gene.

A “paren ” protein, enzyme, polynucleotide, gene, or cell,
is any protein, enzyme, polynucleotide, gene, or cell, from
Which any other protein, enzyme, polynucleotide, gene, or
cell, is derived or made, using any methods, tools or tech
niques, and Whether or not the parent is itself native or mutant.

assay.

A parent polynucleotide or gene encodes for a parent protein

FIG. 9 depicts the enzyme activity of puri?ed BBS protein,
activity associated With a B. braunii lysate (boty lys), and
BBS combined With lysate (BBS+boty lys) With or Without

or enzyme.
40

This includes any mutation in Which a protein, enzyme, poly
nucleotide, or gene sequence is altered, and any detectable
change in a cell arising from such a mutation. Typically, a

NADPH. BBS containing an N-terminal hexa-histidine tag

(SEQ ID NO: 44) Was expressed in E. coli and puri?ed from

bacterial lysate by nickel af?nity chromatography according

mutation occurs in a polynucleotide or gene sequence, by

to the manufacturer (Novagen) (see FIG. 7).
FIG. 10 depicts GC chromatographs of hexane extracts

45

prepared from TN7 yeast (a) and TN7 yeast expressing BBS
(b). The mass spectrum for the unique peak found in the
TN7-BBS culture With a retention time of 16.20 is shoWn in
panel c. The mass spectrum matches that of presqualene
alcohol (PSOH) as described by Edmond et al. (1971) .1. Biol.
Chem. 6254-6251.
FIG. 11 depicts GC chromatographs of hexane extracts

A “mutation” means any process or mechanism resulting
in a mutant protein, enzyme, polynucleotide, gene, or cell.

50

point mutations, deletions, or insertions of single or multiple
nucleotide residues. A mutation includes polynucleotide
alterations arising Within a protein-encoding region of a gene
as Well as alterations in regions outside of a protein-encoding
sequence, such as, but not limited to, regulatory or promoter
sequences. A mutation in a gene can be “silent”, i.e., not

re?ected in an amino acid alteration upon expression, leading
to a “sequence-conservative” variant of the gene. This gener

prepared from TN7 yeast (a) and TN7 yeast expressing a full

ally arises because of degeneracy of the genetic code Wherein

length B. braunii squalene synthase gene (b). Identi?cation of
the novel compound accumulating in TN7 yeast expressing
the squalene synthase gene (corresponding to the peak With

more than one codon codes for the same amino acid.
55

Non-limiting examples of a modi?ed amino acid include a
glycosylated amino acid, a sulfated amino acid, a prenlyated

retention time of approximately 14) Was based on mass spec

(e.g., farnesylated, geranylgeranylated) amino acid, an acety

tral comparisons (not shoWn) and identical chromatographic

lated amino acid, an acylated amino acid, a pegylated amino
acid, a biotinylated amino acid, a carboxylated amino acid, a
phosphorylated amino acid, and the like. References
adequate to guide one of skill in the modi?cation of amino

behavior of an authentic squalene (25 ng) standard (c).
FIG. 12 depicts the accumulation of squalene in TN7 yeast
over-expressing a Bolryococcus braunii squalene synthase

60

acids are replete throughout the literature. Example protocols

gene.

are found in Walker (1998) Protein Protocols on CD-ROM

DETAILED DESCRIPTION OF THE INVENTION

(Humana Press, ToWata, N.J.).
65

The current disclosure describes the functional identi?ca
tion and characterization of the gene coding for a botryococ

Recombinant methods for producing and isolating the trit
erpene synthase polypeptides and modi?ed triterpene syn
thase polypeptides of the invention are described herein. In

US 8,592,180 B2
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addition to recombinant production, the polypeptides may be

centration or Weight), or in terms of a?inity or dissociation

produced by direct peptide synthesis using solid-phase tech

constants. As used interchangeably herein a “triterpene syn

niques (e.g., Stewart et al. (1969) Solid-Phase Peptide Syn
thesis (WH Freeman Co, San Francisco); and Merri?eld

thase activity”, “biological activity of triterpene synthase” or
“functional activity of triterpene synthase”, refers to an activ

(1963) .1. Am. Chem. Soc. 85: 2149-2154; each of Which is

ity exerted by a triterpene synthase protein, polypeptide or

incorporated by reference). Peptide synthesis may be per

nucleic acid molecule on a triterpene synthase polypeptide
substrate, as determined in vivo, or in vitro, according to

formed using manual techniques or by automation. Auto

standard techniques.

mated synthesis may be achieved, for example, using Applied
Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster
City, Calif.) in accordance With the instructions provided by

One of skill in the art Will appreciate that many conserva
tive substitutions of the nucleic acid constructs Which are

the manufacturer.
A “protein” or “polypeptide”, Which terms are used inter
changeably herein, comprises one or more chains of chemical

disclosed herein yield a functionally identical construct. For

example, oWing to the degeneracy of the genetic code, “silent
substitutions” (i.e., substitutions in a nucleic acid sequence
Which do not result in an alteration in an encoded polypep
tide) are an implied feature of every nucleic acid sequence
Which encodes an amino acid.

building blocks called amino acids that are linked together by
chemical bonds called peptide bonds. An “enzyme” means

any substance, composed Wholly or largely of protein, that
catalyzes or promotes, more or less speci?cally, one or more

Similarly, “conservative amino acid substitutions,” in

chemical or biochemical reactions. A “native” or “Wild-type”
protein, enzyme, polynucleotide, gene, or cell, means a pro
tein, enzyme, polynucleotide, gene, or cell that occurs in

Which one or a feW amino acids in an amino acid sequence are
20

nature (Who se form predominates in natural populations).

to a disclosed construct. Families of amino acid residues

having similar side chains have been de?ned in the art. These
families include amino acids With basic side chains (e.g.,

Accordingly, in various embodiments, isolated or recom

binant polypeptides comprising the amino acid sequence set
forth in SEQ ID NO:2 are provided. The polypeptides include
up to 35, 25, 10, 5, 4, 3, 2 or 1 conservative amino acid
substitutions.
“Conservative amino acid substitutions” or, simply, “con
servative variations” of a particular sequence refers to the
replacement of one amino acid, or series of amino acids, With
essentially identical amino acid or series of amino acids. One

25

30

herein.
It Will be appreciated by those skilled in the art that due to
35

the degeneracy of the genetic code, a multitude of nucleotide

sequences encoding modi?ed triterpene synthase polypep
tides of the invention may be produced, some of Which bear

40

Serine (S), and Threonine (T). Another conservative substi
tution group includes Aspartic acid (D) and Glutamic acid
(E). Another conservative substitution group includes Aspar
agine (N) and Glutamine (Q). Yet another conservative sub

stitution group includes Arginine (R) and Lysine (K). Another

beta-branched side chains (e.g., threonine, valine, isoleucine)
and aromatic side chains (e. g., tyrosine, phenylalanine, tryp
tophan, histidine). Such conservative variations of each dis
closed sequence are a feature of the polypeptides provided

Conservative substitution tables providing functionally
similar amino acids are Well knoWn in the art. For example,
one conservative substitution group includes Alanine (A),

lysine, arginine, histidine), acidic side chains (e.g., aspartic
acid, glutamic acid), uncharged polar side chains (e.g., gly
cine, asparagine, glutamine, serine, threonine, tyrosine, cys
teine), nonpolar side chains (e.g., alanine, valine, leucine,

isoleucine, proline, phenylalanine, methionine, tryptophan),

of skill Will recognize that individual substitutions, deletions
or additions Which alter, add or delete a single amino acid or
a percentage of amino acids in an encoded sequence result in
“conservative variations” Where the alterations result in the
deletion of an amino acid, addition of an amino acid, or
substitution of an amino acid With a functionally similar
amino acid.

substituted With different amino acids With highly similar
properties, are also readily identi?ed as being highly similar

substantial identity to the nucleic acid sequences explicitly
disclosed herein. For instance, codons AGA, AGG, CGA,
CGC, CGG, and CGU all encode the amino acid arginine.
Thus, at every position in the nucleic acid molecules of the
invention Where an arginine is speci?ed by a codon, the codon
can be altered to any of the corresponding codons described

above Without altering the encoded polypeptide. It is under
45

conservative substitution group includes lsoleucine, (1) Leu
cine (L), Methionine (M), and Valine (V). Another conserva

stood that U in an RNA sequence corresponds to T in a DNA
sequence.
“Conservative variants” are proteins or enzymes in Which a

tive substitution group includes Phenylalanine (F), Tyrosine

given amino acid residue has been changed Without altering

(Y), and Tryptophan (W).

overall conformation and function of the protein or enzyme,
including, but not limited to, replacement of an amino acid
With one having similar properties, including polar or non

Thus, “conservative amino acid substitutions” of a listed

50

polypeptide sequence (e.g., SEQ ID NO:2) include substitu

polar character, size, shape and charge. Amino acids other

tions of a percentage, typically less than 10%, of the amino
acids of the polypeptide sequence, With an amino acid of the

than those indicated as conserved may differ in a protein or
enzyme so that the percent protein or amino acid sequence

same conservative substitution group. Accordingly, a conser

vatively substituted variation of a polypeptide of the invention

55

can contain, for example, substitutions of 35, 25, 10, 5, 4, 3,
2 or 1 amino acid With an amino acid of the same conservative

substitution group.
It is understood that the addition of sequences that do not
alter the encoded activity of a nucleic acid molecule, such as

98% or at least 99%, as determined according to an alignment

scheme. As referred to herein, “sequence similarity” means
60

the addition of a non-functional or non-coding sequence, is a

conservative variation of the basic nucleic acid molecule. The
“activity” of an enzyme is a measure of its ability to catalyze
a reaction, i.e., to “function”, and may be expressed as the rate

at Which the product of the reaction is produced. For example,
enzyme activity can be represented as the amount of product
produced per unit of time or per unit of enzyme (e.g., con

similarity betWeen any tWo proteins of similar function may
vary and can be, for example, at least 30%, at least 50%, at
least 70%, at least 80%, at least 90%, at least 95%, at least
the extent to Which nucleotide or protein sequences are
related. The extent of similarity betWeen tWo sequences can

be based on percent sequence identity and/or conservation.
“Sequence identity” herein means the extent to Which tWo
65

nucleotide or amino acid sequences are invariant. “Sequence
alignment” means the process of lining up tWo or more

sequences to achieve maximal levels of identity (and, in the
case of amino acid sequences, conservation) for the purpose
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of assessing the degree of similarity. Numerous methods for
aligning sequences and assessing similarity/identity are

positions in a particular sequence at least 80%, 85%, 90%,

known in the art such as, for example, the Cluster Method,
Wherein similarity is based on the MEGALIGN algorithm, as
Well as BLASTN, BLASTP, and FASTA (Lipman and Pear

95%, 98% or 99% of the time. In other Words, the invention
encompasses polypeptides that contain the recited amino acid
substitutions at 80%, 85%, 90%, 95%, 98% or 99% of the
recited positions in a given sequence. The skilled artisan Will

son, (1985) Science 22; 227(4693):1435-41; Pearson and
Lipman, (1988) Proc Natl Acad Sci USA; 85(8):2444-8).

recogniZe that not every substitution from a group of substi
tutions is necessary to obtain a modi?ed polypeptide that is

When using all of these programs, the preferred settings are
those that results in the highest sequence similarity.
Non-conservative modi?cations of a particular polypep

active on a triterpene substrate:

“Sequence identity” herein means the extent to Which tWo
nucleotide or amino acid sequences are invariant. “Sequence
alignment” means the process of lining up tWo or more

tide are those Which substitute any amino acid not character
iZed as a conservative substitution. For example, any substi
tution Which crosses the bounds of the six groups set forth
above. These include substitutions of basic or acidic amino

sequences to achieve maximal levels of identity (and, in the
case of amino acid sequences, conservation) for the purpose

of assessing the degree of similarity. Numerous methods for
aligning sequences and assessing similarity/identity are

acids for neutral amino acids, (e.g., Asp, Glu, Asn, or Gln for
Val, lle, Leu or Met), aromatic amino acid for basic or acidic

knoWn in the art such as, for example, the Cluster Method,
Wherein similarity is based on the MEGALIGN algorithm, as
Well as BLASTN, BLASTP, and FASTA (Lipman and Pear

amino acids (e.g., Phe, Tyr or Trp for Asp, Asn, Glu or Gln) or
any other substitution not replacing an amino acid With a like

amino acid. Basic amino acids include lysine (K), arginine
(R), histidine (H); acidic amino acids include aspartic acid

20

son, (1985), Pearson and Lipman, (1988)). When using all of

(D), glutamic acid (E); uncharged polar amino acids include

these programs, the preferred settings are those that results in

glycine (G), asparagine (N), glutamine (Q), serine (S), threo
nine (T), tyrosine (Y), cysteine (C); nonpolar amino acids

the highest sequence similarity. For example, the “identity” or
“percent identity” With respect to a particular pair of aligned

include alanine (A), valine (V), leucine (L), isoleucine (I),

proline (P), phenylalanine (F), methionine (M), tryptophan

amino acid sequences can refer to the percent amino acid
25

(W); beta-branched amino acids include threonine (T), valine
(V), isoleucine (I); aromatic amino acids include tyrosine

sequence identity that is obtained by ClustalW analysis (ver
sion W 1.8 available from European Bioinformatics Institute,

ponents With Which it is normally associated (other proteins,

Cambridge, UK), counting the number of identical matches
in the alignment and dividing such number of identical
matches by the greater of (i) the length of the aligned
sequences, and (ii) 96, and using the folloWing default Clust
alW parameters to achieve sloW/accurate pairWise align

nucleic acid molecules, cells, synthetic reagents, etc.). A

mentsiGap Open Penalty: 10; Gap Extension Penalty: 0.10;

nucleic acid molecule or polypeptide is “recombinant” When

Protein Weight matrix: Gonnet series; DNA Weight matrix:
IUB; Toggle SloW/Fast pairWise alignmentsISLOW or
FULL Alignment.

(Y), phenylalanine (F), tryptophan (W), histidine (H).
A polynucleotide, polypeptide, or other component is “iso
lated” When it is partially or completely separated from com

30

it is arti?cial or engineered, or derived from an arti?cial or

engineered protein or nucleic acid molecule. For example, a

35

TWo sequences are “optimally aligned” When they are

polynucleotide that is inserted into a vector or any other
heterologous location, e.g., in a genome of a recombinant

organism, such that it is not associated With nucleotide
sequences that normally ?ank the polynucleotide as it is
found in nature is a recombinant polynucleotide. A protein
expressed in vitro or in vivo from a recombinant polynucle
otide is an example of a recombinant polypeptide. Likewise,
a polynucleotide sequence that does not appear in nature, for
example a variant of a naturally occurring gene, is recombi
nant. For example, an “isolated” nucleic acid molecule is one

aligned for similarity scoring using a de?ned amino acid
substitution matrix (e.g., BLOSUM62), gap existence pen
40

alty and gap extension penalty so as to arrive at the highest
score possible for that pair of sequences. Amino acid substi
tution matrices and their use in quantifying the similarity
betWeen tWo sequences are Well-knoWn in the art and

described, e.g., in Dayhoff et al. (1978) “A model of evolu
45

Which is separated from other nucleic acid molecules Which

tionary change in proteins” in “Atlas of Protein Sequence and
Structure,”Vol. 5, Suppl. 3 (ed. M. O. Dayhoff), pp. 345-352.
Natl. Biomed. Res. Found, Washington, DC. and Henikoffet
al. (1992)Pr0c. Naz’l. Acad. Sci. USA 89: 10915-10919 (each

are present in the natural source of the nucleic acid molecule.

For example, With regards to genomic DNA, the term “iso

of Which is incorporated by reference). The BLOSUM62

lated” includes nucleic acid molecules Which are separated
from the chromosome With Which the genomic DNA is natu
rally associated. Typically, an “isolated” nucleic acid mol
ecule is free of sequences Which naturally ?ank the nucleic
acid molecule (i.e., sequences located at the 5' and 3' ends of

matrix is often used as a default scoring substitution matrix in
50

a single amino acid gap in one of the aligned sequences, and

the nucleic acid molecule) in the genomic DNA of the organ
ism from Which the nucleic acid molecule is derived. For

55

example, in various embodiments, the isolated nucleic acid
molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1
kb, 0.5 kb or 0.1 kb of nucleotide sequences Which naturally
?ank the nucleic acid molecule in genomic DNA of the cell
from Which the nucleic acid molecule is derived. Moreover,

sequence alignment protocols such as Gapped BLAST 2.0.
The gap existence penalty is imposed for the introduction of

the gap extension penalty is imposed for each additional
empty amino acid position inserted into an already opened
gap. The alignment is de?ned by the amino acids positions of
each sequence at Which the alignment begins and ends, and
optionally by the insertion of a gap or multiple gaps in one or
both sequences so as to arrive at the highest possible score.

While optimal alignment and scoring can be accomplished
60

manually, the process is facilitated by the use of a computer

an “isolated” nucleic acid molecule, such as a cDNA mol

implemented alignment algorithm, e.g., gapped BLAST 2.0,

ecule, can be substantially free of other cellular material, or

described in Altschul et al. (1997) Nucl. Acids Res. 25: 3389

culture medium When produced by recombinant techniques,

3402 (incorporated by reference herein), and made available

or substantially free of chemical precursors or other chemi

to the public at the National Center for Biotechnology Infor

cals When chemically synthesiZed.
In some embodiments, a polypeptide provided herein
includes amino acid residue substitutions that correspond to

65

mation (NCB1) Website (WWW.ncbi.nlm.nih.gov). Optimal
alignments, including multiple alignments, can be prepared
using, e.g., PSI-BLAST, available through the NCB1 Website

US 8,592,180 B2
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and described by Altschul et al. (1997) Nucl. Acids Res.

70%, 80%, 90% or 95% identical to the full-length of SEQ ID
N01 5, domain IV comprises an amino acid sequence that is
at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95%
identical to the full-length of SEQ ID N01 6 and domain V
comprises an amino acid sequence that is at least 20%, 305,
40%, 50%, 60%, 70%, 80%, 90% or 95% identical the full
length of SEQ ID N01 7. The 5 peptide domains may be
present in the synthase in any order, preferably the order of the

2513389-3402 (incorporated by reference herein).
With respect to an amino acid sequence that is optimally
aligned With a reference sequence, an amino acid residue

“corresponds to” the position in the reference sequence With
Which the residue is paired in the alignment. The “position” is
denoted by a number that sequentially identi?es each amino
acid in the reference sequence based on its position relative to

5 peptides in the polypeptide is, from its amino to carboxy
terminal, I, II, III, IV, andV, and more preferably the I, II, III,
IV andV domains comprise respectively SEQ ID N01 3, SEQ

the N-terminus. For example, in SEQ ID N012, position 1 is
M, position 2 is T, position 3 is M, etc. When a test sequence
is optimally aligned With SEQ ID N012, a residue in the test
sequence that aligns With the M at position 3 is said to “cor

ID N01 4, SEQ ID N01 5, SEQ ID N016 and SEQ ID N017.

respond to position 3” of SEQ ID N012. Owing to deletions,
insertion, truncations, fusions, etc., that must be taken into
account When determining an optimal alignment, in general

In other embodiments, isolated nucleic acid molecules are
provided. Described herein are nucleic acid molecules that

the amino acid residue number in a test sequence as deter

encode a polypeptide having triterpene synthase activity, in
particular a Bolryococcus braunii triterpene synthase. The

mined by simply counting from the N-terminal Will not nec
essarily be the same as the number of its corresponding posi

nucleic acid molecules of this invention include e.g., nucleic
acid molecules that encode the amino acid sequence set forth

tion in the reference sequence. For example, in a case Where
there is a deletion in an aligned test sequence, there Will be no

20

amino acid that corresponds to a position in the reference
sequence at the site of deletion. Where there is an insertion in
an aligned reference sequence, that insertion Will not corre

in SEQ ID N01 2, nucleic acid molecules that encode frag
ments of SEQ ID N01 2, nucleic acidmolecules that comprise
SEQ ID N011, and nucleic acid molecules that encode frag
ments of SEQ ID N01 1. In one aspect, the invention provides
a novel family of isolated or recombinant polynucleotides
referred to herein as “triterpene synthase polynucleotides” or

spond to any amino acid position in the reference sequence. In
the case of truncations or fusions there can be stretches of 25

“triterpene synthase nucleic acid molecules.” Triterpene syn

amino acids in either the reference or aligned sequence that do
not correspond to any amino acid in the corresponding
sequence.

thase polynucleotide sequences are characterized by the abil

ity to encode a triterpene synthase polypeptide. In general, the
invention includes any nucleotide sequence that encodes any

of the novel triterpene synthase polypeptides described

Also contemplated are fragments of the full length triter

pene synthase polypeptides and polynucleotides, e.g., frag

30

ments of polypeptides comprising the amino acid sequence
set forth in SEQ ID NO: 2 and fragments of nucleic acid
molecules comprising the sequence set forth in SEQ ID N01
1. A “fragment” is a unique portion of a triterpene synthase

polypeptide or the polynucleotide encoding triterpene syn

and “nucleic acid molecule” are used to refer to a polymer of

nucleotides (A, C, T, U, G, etc. or naturally occurring or
arti?cial nucleotide analogues), e. g., DNA or RNA, or a rep

resentation thereof, e. g., a character string, etc., depending on
35

thase Which is identical in sequence to, but shorter in length
than, the parent sequence. A fragment may comprise up to the
entire length of the de?ned sequence, minus one nucleotide/
amino acid residue. For example, a fragment may comprise
from 5 to 1000 contiguous nucleotides or amino acid residues
of a given nucleic acid molecule or polypeptide. A fragment
used as a probe, primer, antigen, catalytic molecule, or for

herein. The terms “polynucleotide,” “nucleotide sequence,”

the relevant context. A given polynucleotide or complemen
tary polynucleotide can be determined from any speci?ed
nucleotide sequence.

In an aspect, the triterpene synthase polynucleotides com
prise recombinant or isolated forms of naturally occurring
40

nucleic acid molecules isolated from an organism, e.g., an

algae strain. Exemplary triterpene synthase polynucleotides
include those that encode the polypeptide set forth in SEQ ID

otherpurposes, maybe atleast 5, 10, 15, 16, 20, 25, 30, 40, 50,

N012. In another aspect of the invention, triterpene synthase

60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or

polynucleotides are produced by diversifying, e.g., mutating,

amino acid residues in length. Fragments may be preferen

45

tially selected from certain regions of a molecule. For
example, a polypeptide fragment may comprise a certain
length of contiguous amino acids selected from the ?rst 250
or 500 amino acids (or ?rst 25% or 50%) of a polypeptide as
shoWn in a certain de?ned sequence. Clearly these lengths are

pene synthase polynucleotides encoding triterpene synthase
50

exemplary, and any length that is supported by the speci?ca
tion, including the Sequence Listing, tables, and ?gures, may
be encompassed by the present embodiments.

polypeptides With superior functional attributes, e. g.,
increased catalytic function, increased stability, or higher

expression level, than a triterpene synthase encoded by the
polynucleotide used as a substrate or parent in the diversi?
cation process.

Also contemplated in this invention are isolated polypep

tides that are triterpene synthases, that comprise 5 peptide
domains I, II, III, IV, andV. The peptide domains I, II, III, IV,

a naturally occurring, isolated, or recombinant triterpene syn
thase polynucleotide, e.g., the nucleic acid sequence set forth
in SEQ ID N01 1. It is possible to generate diversi?ed triter

The polynucleotides of the invention have a variety of uses
55

in, for example recombinant production (i.e., expression) of

and V of the triterpene synthase of this invention may com

the triterpene synthase polypeptides of the invention and as
substrates for further diversity generation, e.g., recombina

prise respectively, e.g., SEQ ID N01 3, SEQ ID N01 4, SEQ

tion reactions or mutation reactions to produce neW and/or

improved triterpene synthase homologues, and the like.

ID N01 5, SEQ ID N01 6, and SEQ ID N01 7 (See FIG. 6, the
5 domains of B. braunii (BBS)). In an embodiment of the

60

at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95%
identical to the full-length of SEQ ID N01 3, domain II
comprises an amino acid sequence that is at least 20%, 30%,
40%, 50%, 60%, 70%, 80%, 90% or 95% identical the full
length of SEQ ID N01 4, domain III may comprise an amino
acid sequence that is at least 20%, 30%, 40%, 50%, 60%,

It is important to note that certain speci?c, substantial and

credible utilities of triterpene synthase polynucleotides do not
require that the polynucleotide encode a polypeptide With

invention, domain I comprises an amino acid sequence that is

substantial triterpene synthase activity or even variant triter

pene synthase activity. For example, triterpene synthase poly
65

nucleotides that do not encode active enZymes can be valu
able sources of parental polynucleotides for use in

diversi?cation procedures to arrive at triterpene synthase
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polynucleotide variants, or non-triterpene synthase poly
nucleotides, With desirable functional properties (e.g., high

sequence. The invention provides each and every possible
variation of nucleic acid sequence encoding a polypeptide of
the invention that could be made by selecting combinations

kcat or kcat/Km, loW Km, high stability towards heat or other
environmental factors, high transcription or translation rates,

based on possible codon choices. These combinations are

resistance to proteolytic cleavage, etc.).

made in accordance With the standard triplet genetic code as
applied to the nucleic acid sequence encoding a triterpene

Triterpene synthase polynucleotides, including nucleotide
sequences that encode triterpene synthase polypeptides and

synthase homologue polypeptide of the invention. All such

variants thereof, fragments of triterpene synthase polypep

variations of every nucleic acid sequence herein are speci?

tides, related fusion proteins, or functional equivalents
thereof, are used in recombinant DNA molecules that direct

cally provided and described by consideration of the
sequence in combination With the genetic code. Any variant

the expression of the triterpene synthase polypeptides in

can be produced as noted herein.

appropriate host cells, such as plant cells. Due to the inherent

In general, the invention includes any polypeptide encoded

degeneracy of the genetic code, other nucleic acid sequences

by a modi?ed triterpene synthase polynucleotide derived by

Which encode substantially the same or a functionally equiva
lent amino acid sequence can also be used to clone and

“host cell”, as used herein, includes any cell type Which is

mutation, recursive sequence recombination, and/or diversi
?cation of the polynucleotide sequences described herein. In
some aspects of the invention, a triterpene synthase polypep
tide is modi?ed by single or multiple amino acid substitu

susceptible to transformation With a nucleic acid construct.

tions, a deletion, an insertion, or a combination of one or more

express the triterpene synthase polynucleotides. The term

of these types of modi?cations. Substitutions can be conser

The term “transformation” means the introduction of a for

eign (i.e., extrinsic or extracellular) gene, DNA or RNA
sequence to a host cell, so that the host cell Will express the
introduced gene or sequence to produce a desired substance,
typically a protein or enzyme coded by the introduced gene or
sequence. The introduced gene or sequence may include
regulatory or control sequences, such as start, stop, promoter,

20

vative or non-conservative, can alter function or not, and can

add neW function. Insertions and deletions can be substantial,
such as the case of a truncation of a substantial fragment of the
sequence, or in the fusion of additional sequence, either inter
nally or at N or C terminal.
25

An aspect of the invention pertains to isolated nucleic acid

signal, secretion, or other sequences used by the genetic

molecules that encode modi?ed triterpene synthase polypep

machinery of the cell. A host cell that receives and expresses

tides or biologically active portions thereof. As used herein,

introduced DNA or RNA has been “transformed” and is a

the term “nucleic acid molecule” is intended to include DNA

“transformant” or a “clone.” The DNA or RNA introduced to

molecules (e.g., cDNA or genomic DNA) and RNA mol
ecules (e.g., mRNA) and analogs of the DNA or RNA gener
ated using nucleotide analogs. The nucleic acid molecule can

a host cell can come from any source, including cells of the
same genus or species as the host cell, or cells of a different

genus or species.
As Will be understood by those of skill in the art, it can be
advantageous to modify a coding sequence to enhance its
expression in a particular host. The genetic code is redundant

30

be single-stranded or double-stranded, but preferably is
35

With 64 possible codons, but most organisms preferentially
use a subset of these codons. The codons that are utilized most

standard molecular biology techniques and the sequence
information provided herein.

often in a species are called optimal codons, and those not
utilized very often are classi?ed as rare or loW-usage codons

(see, e.g., Zhang et al. (1991) Gene 105161-72; incorporated

40

by reference herein). Codons can be substituted to re?ect the
preferred codon usage of the host, a process sometimes called

A nucleic acid molecule of the invention can be ampli?ed
using cDNA, mRNA or alternatively, genomic DNA, as a

template and appropriate oligonucleotide primers according

“codon optimization” or “controlling for species codon bias.”

to standard PCR ampli?cation techniques. The nucleic acid

Optimized coding sequences containing codons preferred
by a particular prokaryotic or eukaryotic host (see also, Mur
ray et al. (1 989) Nucl. Acids Res. 171477-508; incorporated by

double-stranded DNA.
A nucleic acid molecule of the present invention, e.g., a
nucleic acid molecule that encodes a polypeptide set forth in
SEQ ID NO12, or having the nucleotide sequence of set forth
in SEQ ID NO: 1, or a portion thereof, can be isolated using

molecule so ampli?ed can be cloned into an appropriate vec
45

tor and characterized by DNA sequence analysis. Further
more, oligonucleotides corresponding to nucleotide

reference herein) can be prepared, for example, to increase

sequences can be prepared by standard synthetic techniques,

the rate of translation or to produce recombinant RNA tran

e.g., using an automated DNA synthesizer. In some embodi
ments, an isolated nucleic acid molecule of the invention
comprises a nucleic acid molecule Which is a complement of
a nucleotide sequence encoding a polypeptide set forth in
SEQ ID NO12, or complement of the nucleotide sequence set
forth in SEQ ID NO11. In still another embodiment, an iso
lated nucleic acid molecule of the invention comprises a

scripts having desirable properties, such as a longer half-life,
as compared With transcripts produced from a non-optimized

50

sequence. Translation stop codons can also be modi?ed to

re?ect host preference. For example, preferred stop codons
for S. cerevisiae and mammals are UAA and UGA, respec

tively. The preferred stop codon for monocotyledonous plants
is UGA, Whereas insects and E. coli prefer to use UAA as the

55

nucleotide sequence Which is at least about 50%, 52%, 55%,

stop codon (Dalphin et al. (1996) Nucl. Acids Res. 24: 216

60%, 62%, 65%, 70%, 75%, 78%, 80%, 85%, 88%, 90%,

218; incorporated by reference herein). Methodology for

95%, 97%, 98% or more identical to the nucleotide sequence

optimizing a nucleotide sequence for expression in a plant is
provided, for example, in US. Pat. No. 6,015,891, and the
“Silent variations” are one species of “conservative substi
tutions.” One of skill Will recognize that each codon in a

encoding a polypeptide set forth in SEQ ID NO12, or the
nucleotide sequence set forth in SEQ ID NO: 1, or a portion of
any of these nucleotide sequences.
In addition to the nucleotide sequences encoding a
polypeptide set forth in SEQ ID NO12, or the nucleotide

nucleic acid sequence (except AUG, Which is ordinarily the
only codon for methionine) can be modi?ed by standard
techniques to encode a functionally identical polypeptide.

those skilled in the art that DNA sequence polymorphisms
that lead to changes in the amino acid sequences of the pro

references cited therein (incorporated herein by reference).

Accordingly, each silent variation of a nucleic acid sequence
that encodes a polypeptide is implicit in any described

60

sequence set forth in SEQ ID NO: 1, it Will be appreciated by
65

teins may exist Within a population. Such genetic polymor
phisms may exist among individuals Within a population due
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to natural allelic variation. Such natural allelic variations
include both functional and non-functional proteins and can
typically result in 1-5% variance in the nucleotide sequence
of a gene. Any and all such nucleotide variations and resulting
amino acid polymorphisms in genes that are the result of
natural allelic variation and that do not alter the functional
activity of a protein are intended to be Within the scope of the
invention.
Accordingly, in another embodiment, an isolated nucleic

ing of SEQ ID N01 1. Preferably the nucleic acid molecule
that hybridizes encodes a polypeptide having triterpene syn

thase activity.
The skilled artisan Will appreciate that changes can be
introduced by mutation into the nucleotide sequences of any
nucleic acid sequence encoding a polypeptide set forth in
SEQ ID N012, or having the nucleotide sequence set forth in

SEQ ID N011, thereby leading to changes in the amino acid
sequence of the encoded proteins. In some cases the alteration
Will lead to altered function of the polypeptide. In other cases

acid molecule of the invention hybridizes under stringent

the change Will not alter the functional ability of the encoded
polypeptide. In general, substitutions that do not alter the
function of a polypeptide include nucleotide substitutions
leading to amino acid substitutions at “non-essential” amino
acid residues. Generally these substitutions can be made in,
for example, the sequence encoding a polypeptide set forth in
SEQ ID N012, or having the nucleotide sequence set forth in
SEQ ID N011, Without altering the ability of the enzyme to
catalyze the reductive condensation of FPP substrate. A “non

conditions to a nucleic acid molecule comprising the nucle

otide sequence encoding a polypeptide set forth in SEQ ID
N012, or the nucleotide sequence set forth in SEQ ID N011.
In other embodiments, the nucleic acidmolecule is at least 30,

50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, or 600
nucleotides in length. Nucleic acid molecules are “hybridiz
able” to each other When at least one strand of one polynucle
otide can anneal to another polynucleotide under de?ned

stringency conditions. Stringency of hybridization is deter
mined, e.g., by (a) the temperature at Which hybridization
and/or Washing is performed, and (b) the ionic strength and

20

activity of the resulting polypeptide, e.g., catalyzing the

polarity (e.g., formamide) of the hybridization and Washing
solutions, as Well as other parameters. Hybridization requires

that the tWo polynucleotides contain substantially comple
mentary sequences; depending on the stringency of hybrid
ization, hoWever, mismatches may be tolerated. Typically,
hybridization of tWo sequences at high stringency (such as,

25

Will generally not constitute “conservative” substitutions.
Instead, these substitutions constitute non-conservative sub
30

stitutions introduced in to a sequence in order to obtain a neW

or improved activity.

complementarity over their entire sequence. Conditions of

intermediate stringency (such as, for example, an aqueous
solution of 2><SSC at 650 C.) and loW stringency (such as, for
example, an aqueous solution of 2><SSC at 55° C.), require
correspondingly less overall complementarity betWeen the
hybridizing sequences (1><SSC is 0.15 M NaCl, 0.015 M Na

reductive condensation of 2 FPP to yield botryococcene.
Also contemplated are those situations Where it is desirable
to alter the activity of a parent polypeptide such that the
polypeptide has neW or increased activity on a particular
substrate. It is understood that these amino acid substitutions

for example, in an aqueous solution of 0.5><SSC at 65° C.)

requires that the sequences exhibit some high degree of

essential” amino acid residue is a residue that can be altered

from the parent sequence Without altering the biological

It is also understood that an isolated nucleic acid molecule

encoding a polypeptide homologous to the polypeptide of
35

SEQ ID N012 can be created by introducing one or more
nucleotide substitutions, additions or deletions into the nucle

otide sequence encoding the particular polypeptide, such that
one or more amino acid substitutions, additions or deletions

citrate).

are introduced into the encoded protein. Mutations can be

Nucleic acid molecules that hybridize include those Which
anneal under suitable stringency conditions and Which
encode polypeptides or enzymes having the same function,
such as the ability to catalyze the reductive condensation of 2

introduced into the nucleic acid sequence by standard tech
niques, such as site-directed mutagenesis and PCR-mediated
mutagenesis. In contrast to those positions Where it may be

40

desirable to make a non-conservative amino acid substitu

famexyl diphosphate (FPP) substrate molecules yielding bot

tions (see above), in some positions it is preferable to make
conservative amino acid substitutions.

ryococcene, a 30-carbon branched-chain hydrocarbon, of the

invention. Further, the term “hybridizes under stringent con
ditions” is intended to describe conditions for hybridization
and Washing under Which nucleotide sequences at least 30%,
40%, 50%, or 60% homologous to each other typically
remain hybridized to each other. Preferably, the conditions

45

are such that sequences at least about 70%, more preferably at
least about 80%, even more preferably at least about 85% or

50

Mutational methods of generating diversity include, for
example, site-directed mutagenesis (Ling et al. (1997) Anal
Brioche. 254(2)1 157-178; Dale et al. (1996) Methods Mol.
Biol. 571369-374; Smith (1985)Ann. Rev. Genet. 191423-462;
Botstein & Shortle (1985) Science 22911193-1201; Carter
(1986) Biochem. J. 23711-7; and Kunkel (1987) “The e?i
ciency of oligonucleotide directed mutagenesis” in Nucleic

90% homologous to each other typically remain hybridized to

Acids & Molecular Biology (Eckstein, F. and Lilley, D. M. J .

each other. In some cases, an isolated nucleic acid molecule of

eds., Springer Verlag, Berlin)); mutagenesis using uracil con
taining templates (Kunkel (1985) Proc. Natl. Acad. Sci. USA
821488-492; Kunkel et al. (1987) Methods in Enzymol. 154,
367-382; and Bass et al. (1988) Science 2421240-245); oligo
nucleotide-directed mutagenesis (Methods in Enzymol. 1001
468-500 (1983); Methods in Enzymol. 1541 329-350 (1987);

the invention that hybridizes under stringent conditions to a
nucleic acid sequence encoding a polypeptide set forth in any
of SEQ ID N012, or the nucleotide sequence set forth in SEQ
ID N011, corresponds to a naturally-occurring nucleic acid
molecule. As used herein, a “naturally-occurring” nucleic
acid molecule refers to an RNA or DNA molecule having a
nucleotide sequence that occurs in nature (e.g., encodes a
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natural protein). Preferably the nucleic acid molecule that
hybridizes, hybridizes to at least 30%, 40%, 50%, 60%, 70%,

350); phosphorothioate-modi?ed DNA mutagenesis (Taylor

80%, 85% or 90% of the length of a nucleic acid molecule

consisting of SEQ ID N011 under stringent conditions. More
preferably the nucleic acid molecule that hybridizes, hybrid
izes to at least about 80%, even more preferably at least about
85% or 90% of the length of a nucleic acid molecule consist

Zoller & Smith (1982) Nucleic Acids Res. 1016487-6500;
Zoller & Smith (1983) Methods in Enzymol. 1001468-500;
and Zoller & Smith (1987) Methods in Enzymol. 1541329
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et al. (1985) Nucl. Acids Res. 131 8749-8764; Taylor et al.
(1985) Nucl. Acids Res. 131 8765-8787; Nakamaye & Eck
stein (1986) Nucl. Acids Res. 141 9679-9698; Sayers et al.
(1988) Nucl. Acids Res. 161791-802; and Sayers et al. (1988)

Nucl. Acids Res. 161 803-814); mutagenesis using gapped

US 8,592,180 B2
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duplex DNA (Kramer et al. (1984)Nucl. Acids Res. 12: 9441 -

operably linked to the sequence. Large numbers of suitable

9456; Kramer & FritZ (1987) Methods in Enzymol. 154:350
367; Kramer et al. (1988)Nucl. Acids Res. 16: 7207; and Fritz
et al. (1988) Nucl. Acids Res. 16: 6987-6999) (each ofWhich

vectors and promoters are knoWn to those of skill in the art,
and are commercially available.
Accordingly, in other embodiments, vectors that include a
nucleic acid molecule of the invention are provided.
In other embodiments, host cells transfected With a nucleic

is incorporated by reference).
Additional suitable methods include point mismatch repair

(Kramer et al. (1984) Cell 38:879-887), mutagenesis using

acid molecule of the invention, or a vector that includes a

repair-de?cient host strains (Carter et al. (1985) Nucl. Acids
Res. 13: 4431-4443; and Carter (1987) Methods in Enzymol.

nucleic acid molecule of the invention, are provided. Host
cells include eucaryotic cells such as yeast cells, e.g., yeast
cells having a ERGl knockout, e.g., the yeast strain TN7

154: 382-403), deletion mutagenesis (EghtedarZadeh &
Henikoff (1986) Nucl. Acids Res. 14: 5115), restriction-se
lection and restriction-puri?cation (Wells et al. (1986) Phil.
Trans. R. Soc. Lond. A 317: 415-423), mutagenesis by total
gene synthesis (Nambiar et al. (1984) Science 223: 1299
1301; Sakamar and Khorana (1988) Nucl. Acids Res. 14:
6361 -6372; Wells et al. (1985) Gene 34:315-323; and Grund
strom et al. (1985) Nucl. Acids Res. 13: 3305-3316); double

strand break repair (Mandecki (1 986) ; Arnold (1993) Current
Opinion in Biotechnology 4:450-455; and Proc. Natl. Acad.
Sci. USA, 83:7177-7181) (each of Which is incorporated by

described in co-pending application Ser. No. 12/489,038
incorporated herein in its entirety, insect cells, animal cells, or
plant cells (e. g., algal cells or terrestrial plant cells). Host cells
also include procaryotic cells such as bacterial cells.
The terms “vector”, “vector construct” and “expression
vector” mean the vehicle by Which a DNA or RNA sequence
(eg a foreign gene) can be introduced into a host cell, so as
20

reference). Additional details on many of the above methods
can be found in Methods in Enzymology (1987) Volume 154,

Which also describes useful controls for trouble-shooting

problems With various mutagenesis methods.
Additional details regarding various diversity generating

enZyme technology. A common type of vector is a “plasmid”,
Which generally is a self-contained molecule of double
25

methods can be found in the folloWing U.S. patents, PCT

publications, and EPO publications: U.S. Pat. No. 5,605,793
to Stemmer (Feb. 25, 1997); Us. Pat. No. 5,81 1,238 to Stem
meret al. (Sep. 22, 1998); Us. Pat. No. 5,830,721 to Stemmer
et al. (Nov. 3, 1998); Us. Pat. No. 5,834,252 to Stemmer, et
al. (Nov. 10, 1998); Us. Pat. No. 5,837,458 to Minshull, et al.

cell. A large number of vectors, including plasmid and viral
vectors, have been described for replication and/or expression

in a variety of eukaryotic and prokaryotic hosts. Non-limiting
30

96/33207 by Stemmer and LipschutZ; WO 97/20078 by

Crameri; EP 0932670 by Stemmer; WO 99/23107 by Stem
mer et al.; WO 99/21979 by Apt et al.; WO 98/31837 by del
Cardayre et al.; WO 98/27230 by Patten and Stemmer; WO
98/13487 by Stemmer et al.; WO 00/00632; WO 00/09679;
WO 98/42832 by Arnold et al.; WO 99/29902 byArnold et al.;
WO 98/41653 by Vind; WO 98/41622 by Borchert et al.; WO
98/42727 by Pati and Zarling; WO 00/18906 by Patten et al.;
WO 00/04190 by del Cardayre et al.; WO 00/42561 by
Crameri et al.; WO 00/42559 by Selifonov and Stemmer; WO
00/42560 by Selifonov et al.; WO 01/23401 by Welch et al.;
and W0 01/ 64864 by Affholter (each of Which is incorpo
rated by reference). The QUICKCHANGETM protocol mar
keted by Stratagene of San Diego, Calif. is one speci?c

examples include pKK plasmids (Clonetech), pUC plasmids,
pET plasmids (Novagen, Inc., Madison, Wis.), pRSET or
pREP plasmids (lnvitrogen, San Diego, Calif), pMAL plas
mids (NeW England Biolabs, Beverly, Mass.), and Ti plasmid
vectors, and many appropriate host cells, using methods dis
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closed or cited herein or otherWise knoWn to those skilled in
the relevant art. Vectors can also be selected such that expres

sion of the introduced sequence is targeted to a chloroplast in
a plant cell. Recombinant cloning vectors Will often include
one or more replication systems for cloning or expression,
40

one or more markers for selection in the host, e. g., antibiotic
resistance, and one or more expression cassettes.

The terms “express” and “expression” mean alloWing or
causing the information in a gene or DNA sequence to
45

become manifest, for example producing a protein by acti
vating the cellular functions involved in transcription and
translation of a corresponding gene or DNA sequence. A
DNA sequence is expressed in or by a cell to form an “expres

50

method known to those skilled in the art for introducing
site-directed mutations. This method relies on the use of oligo

sion product” such as a protein. The expression product itself,
eg the resulting protein, may also be said to be “expressed”
by the cell. A polynucleotide or polypeptide is expressed
recombinantly, for example, When it is expressed or produced
in a foreign host cell under the control of a foreign or native
promoter, or in a native host cell under the control of a foreign

or DNA primer pairs, harboring speci?c DNA sequence
changes to be introduced, annealed to the target DNA or gene
to be modi?ed. Copies of modi?ed DNA/ gene are ampli?ed

stranded DNA that can readily accept additional (foreign)
DNA and Which can readily introduced into a suitable host

(Nov. 17, 1998); WO 95/22625, Stemmer and Crameri; WO
Stemmer and Crameri; W0 97/ 35966 by Minshull and Stem
mer; WO 99/41402 by Punnonen et al.; WO 99/41383 by
Punnonen et al.; WO 99/41369 by Punnonen et al.; WO
99/41368 by Punnonen et al.; EP 752008 by Stemmer and

to transform the host and promote expression (e.g. transcrip
tion and translation) of the introduced sequence. Vectors typi
cally comprise the DNA of a transmissible agent, into Which
foreign DNA encoding a protein is inserted by restriction

promoter.
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Polynucleotides provided herein can be incorporated into

by standard PCR methodology. Con?rmation of alteration of
the target DNA sequence is veri?able by automated DNA

ing a polypeptide. Suitable vectors include chromosomal,

sequencing.

nonchromosomal and synthetic DNA sequences, e. g., deriva

Also provided are recombinant constructs comprising one
or more of the nucleic acid sequences as broadly described

above. The constructs comprise a vector, such as, a plasmid,
a cosmid, a phage, a virus, a bacterial arti?cial chromosome

(BAC), a yeast arti?cial chromosome (YAC), or the like, into
Which a nucleic acid sequence of the invention has been

any one of a variety of expression vectors suitable for express

tives of SV40; bacterial plasmids; phage DNA; baculovirus;
60

yeast plasmids; vectors derived from combinations of plas
mids and phage DNA, viral DNA such as vaccinia, adenovi
rus, foWl pox virus, pseudorabies, adenovirus, adeno-associ

ated viruses, retroviruses; Ti plasmids for the incorporation
and expression of DNA in plant cells, and many others. Any

inserted, in a forWard or reverse orientation. In a preferred 65 vector that transduces genetic material into a cell, and, if

aspect of this embodiment, the construct further comprises
regulatory sequences including, for example, a promoter

replication is desired, Which is replicable and viable in the
relevant host can be used.

